Financials in USD. Standardized financial statements.
A compact view of how Health Sciences Acquisitions Corporation 2 turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue? | $33.48M | $2.64M | $0 | $0 | $0 |
| Revenue Growth? | +1169.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $190,000 | $204,000 | $0 | $0 | $0 |
| Gross Profit? | $33.29M | $2.43M | $0 | $0 | $0 |
| Gross Margin? | +99.4% | +92.3% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $85.10M | $66.73M | $2.96M | $274,756 | $179,986 |
| Operating Income? | -$51.81M | -$64.30M | -$3.08M | -$394,756 | -$173,542 |
| EBITDA? | -$51.81M | -$64.30M | -$2.74M | -$378,753 | -$173,542 |
| Income Before Tax | -$52.95M | -$61.02M | -$2.74M | -$378,753 | -$173,542 |
| Income Tax Expense | $0 | $0 | -$345,141 | -$16,003 | $0 |
| Net Income? | -$52.95M | -$61.02M | -$2.39M | -$362,750 | -$173,542 |
| EPS? | $-1.11 | $-1.66 | $-0.15 | $-0.02 | $-0.01 |
| Diluted EPS? | $-1.11 | $-1.66 | $-0.15 | $-0.02 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality